Advanced unresectable classic Kaposi sarcoma relapsed and/or refractory to previous standard treatments. research hub

A Phase II single-arm study of pembrolizumab plus lenvatinib in previously treated classic Kaposi sarcoma (CKS)

This study is looking at a new combination treatment for a type of cancer called Kaposi sarcoma that has come back or not responded to previous treatments. It uses two drugs, pembrolizumab and lenvatinib, to see how well they work together.